News | September 06, 2011

New European Antiplatelet Drug, Diagnostic Test Guidelines Updated

September 6, 2011 — The European Society of Cardiology (ESC) released the latest version of its guidelines for managing patients presenting without persistent ST-segment elevation. This version replaces earlier editions of 2000, 2002 and 2007. The new guidelines also incorporate the findings of very recent studies.

Among the notable new inclusions are recommendations on the use of the new antiplatelet drugs ticagrelor and prasugrel, which only became available in the past two years.

Ticagrelor is recommended for all patients at moderate-to-high risk of ischemic events (including those pre-treated with clopidogrel) and patients with unknown coronary anatomy. Prasugrel is recommended for those who are "clopidogrel naive" in whom coronary anatomy is known and who are proceeding to percutaneous coronary intervention (PCI); prasugrel should be avoided if there is a high risk of life-threatening bleeding or other contraindications. Clopidogrel is reserved for those patients who cannot take either medication.

The guidelines cite the PLATelet inhibition and patient Outcomes (PLATO) and TRITON-TIMI 38 trials as evidence of the superiority of the new drugs over clopidogrel.

There are also notable introductions in the sections on diagnosis. Risk stratification now takes into account the introduction of high-sensitivity troponin assays. These have largely replaced conventional troponin assays because of their higher diagnostic sensitivity. Accordingly, the new guidelines recommend the implementation of a rapid rule-out protocol when these high-sensitivity assays are available. It seems likely the guidelines will change practice in this diagnostic work-up when applying this fast-track protocol.

However, whatever the new introductions, the range of non-ST segment elevation acute coronary syndromes remains as wide and as frequent as ever. The guidelines put annual incidence at three per thousand population, with patients described as a heterogenous group with a variable prognosis. Risk stratification thus remains essential to their management.

The 2011 guidelines recommend use of the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) risk score to estimate the risk of in-hospital bleeding. The score should be used for patients with suspected non-ST-elevation acute coronary syndromes, as bleeding is still acknowledged as a major factor.

“It’s probably the best validated score because it’s based on more than 70,000 patients of the CRUSADE registry and was validated in a cohort of [more than] 17,000 patients,” says task force chairman Prof. Christian Hamm. “So it’s really very solid data.”

Previous guidelines have recommended the GRACE risk score to predict ischemic events. However, says Hamm, the new recommendation to also use the CRUSADE score will enable doctors to tailor treatment according to both risk scores. This, he adds, along with the introduction of high-sensitive troponin assays for diagnosis, are two "practice-changing" recommendations of the new guidelines.

For more information: www.escardio.org

Related Content

Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Overlay Init